Effects of AG-348, a Pyruvate Kinase Activator, on Anemia and Hemolysis in Patients with Pyruvate Kinase Deficiency: Data from the DRIVE PK Study
Rachael F. Grace(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Bertil Glader(Stanford University), Hua Yang(China Pharmaceutical University), Hassan M. Yaish(Primary Children's Hospital), Wilma Barcellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Bruce A. Silver(Johns Hopkins Hospital), D. Holmes Morton(Clinic for Special Children), Penelope A. Kosinski(Agios Pharmaceuticals (United States)), Jeffrey Hixon(Q Therapeutics (United States)), Lee Silverman(Agios Pharmaceuticals (United States)), Elizabeth Merica(Agios Pharmaceuticals (United States)), Yaddanapudi Ravindranath(The Barbara Ann Karmanos Cancer Institute), Kevin H.M. Kuo(University Health Network), Frederic Galactéros(Inserm), Janet L. Kwiatkowski(Children's Hospital of Philadelphia), Ann Barbier(Agios Pharmaceuticals (United States)), Christian Rosé(Klinik und Poliklinik für Hautkrankheiten), Zheng Yuan(Agios Pharmaceuticals (United States)), Marvin B. Cohen(La Roche College), D. Mark Layton(Imperial College Healthcare NHS Trust), Lenny Dang(Millennium Engineering and Integration (United States)), Charles Kung(Agios Pharmaceuticals (United States)), Eduard J. van Beers(Utrecht University)
Cited by 6
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma
|Cancer Cell|2007|949
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations
|Cancer Discovery|2017|457
Ribosomal Protein L5 and L11 Mutations Are Associated with Cleft Palate and Abnormal Thumbs in Diamond-Blackfan Anemia Patients
|The American Journal of Human Genetics|2008|417